Acarbose

Key Research Papers and Clinical Trials

The available evidence for acarbose consists primarily of completed clinical trials and several research papers focused on α-glucosidase inhibitors, though direct acarbose-specific studies are limited in this dataset.

Clinical Trial Evidence

The most relevant clinical research includes several completed Phase 3 trials examining acarbose in combination therapies. A Phase 3 study (NCT01177384) evaluated the safety and efficacy of adding sitagliptin to acarbose monotherapy in participants with type 2 diabetes mellitus, though specific sample sizes and outcomes are not provided in the available data. Another Phase 3 trial (NCT01242202) assessed ASP1941 in combination with α-glucosidase inhibitors in type 2 diabetic patients.

A completed study (NCT04665570) specifically examined how acarbose and metformin work together in Indian patients recently diagnosed with type 2 diabetes, focusing on both efficacy and safety outcomes. Additionally, a Phase 1 bioequivalence study (NCT01554631) compared an orally disintegrating tablet formulation of acarbose (Glucobay ODT 100mg) with the standard tablet formulation.

Research Paper Evidence

The research literature provided focuses primarily on novel α-glucosidase inhibitors rather than acarbose specifically. Several 2026 studies examined synthetic compounds as potential α-glucosidase inhibitors, including adamantane-1,2,3-triazole hybrids and imidazo[1,2-a]pyridine-based inhibitors, using in vitro and computational approaches. Natural product research investigated compounds from Cassia javanica flowers and Asphodelus microcarpus for α-amylase and α-glucosidase inhibitory activity.

One study examined oroxyloside's inhibition of α-amylase/α-glucosidase through spectral analysis and computer simulation, while another investigated longevity interventions in mice that may relate to metabolic pathways relevant to diabetes management.

Evidence Limitations

The available evidence provides limited direct clinical outcome data for acarbose. While several clinical trials are completed, detailed results including sample sizes, primary endpoints, and statistical outcomes are not provided in this dataset. The research papers focus on related compounds and mechanisms rather than acarbose-specific studies, making it difficult to draw firm conclusions about acarbose's clinical efficacy and safety profile from this particular evidence set.

This synthesis is based solely on the provided evidence. For comprehensive clinical guidance regarding acarbose, consult current medical literature and prescribing information.